Related references
Note: Only part of the references are listed.PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
Frederic Bibeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab
Fernando Rivera et al.
ACTA ONCOLOGICA (2008)
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
R. Rosell et al.
ANNALS OF ONCOLOGY (2008)
Cetuximab, its clinical use and future perspectives
Fernando Rivera et al.
ANTI-CANCER DRUGS (2008)
Novel human antibody therapeutics: The age of the Umabs
Sigrid R. Ruuls et al.
Biotechnology Journal (2008)
KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience
E. Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
EPIC:: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
Alberto F. Sobrero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations
Matthias Peipp et al.
JOURNAL OF IMMUNOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
被撤回的出版物: The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility (Retracted article. See vol. 109, pg. 5548, 2012)
Jeroen J. Larnmerts van Bueren et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small-cell lung cancer
Charles A. Butts et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Overexpression of epidermal growth factor type-l receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease
Stefania Bellone et al.
GYNECOLOGIC ONCOLOGY (2007)
FCGR2A and FCGR3A Polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab
Wu Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
Andrea Sartore-Bianchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC)
Thomas J. Lynch et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor -: Positive premenopausal breast cancer
Jennifer M. Giltnane et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
W. Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
R. Hitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma
Christopher E. Pelloski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Her signaling in pancreatic cancer
Barbara Burtness
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: A call for standardized methods for immunohistochemical evaluation
David Cohen et al.
CLINICAL GENITOURINARY CANCER (2007)
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
Jan B. Vermorken et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Human epidermal growth factor receptor 2 testing recommendation - In reply
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cetuximab in the treatment of head and neck cancer
Jacques Bernier
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
Integration of EGFR inhibitors with radiochemotherapy
Mukesh K. Nyati et al.
NATURE REVIEWS CANCER (2006)
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127
Tomislav Dragovich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: Implications for the mechanisms of action
Jeroen J. Lannnerts van Bueren et al.
CANCER RESEARCH (2006)
The evolving role of cetuximab in non-small cell lung cancer
Rogerio C. Lilenbaum
CLINICAL CANCER RESEARCH (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Current status of cetuximab for the treatment of patients with solid tumors
DA Frieze et al.
ANNALS OF PHARMACOTHERAPY (2006)
The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer
J Edwards et al.
CLINICAL CANCER RESEARCH (2006)
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas
Christine H. Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study
B Burtness et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme
RJ Raizer
JOURNAL OF NEURO-ONCOLOGY (2005)
Assessing epidermal growth factor receptor expression in tumours: What is the value of current test methods?
AP Dei Tos et al.
EUROPEAN JOURNAL OF CANCER (2005)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni et al.
LANCET ONCOLOGY (2005)
Is immunohistochemistry for epidermal growth factor receptor expression a poor predictor of response to epidermal growth factor receptor-targeted therapy?
M Younes
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy
R Hitt et al.
EUROPEAN JOURNAL OF CANCER (2005)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies
M Scartozzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues:: Variation in staining intensity due to choice of fixative and storage time of tissue sections
D Atkins et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2004)
Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy
WK Bleeker et al.
JOURNAL OF IMMUNOLOGY (2004)